Zacks Investment Management Allogene Therapeutics, Inc. Transaction History
Zacks Investment Management
- $11.4 Billion
- Q3 2024
A detailed history of Zacks Investment Management transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Zacks Investment Management holds 516,601 shares of ALLO stock, worth $1.32 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
516,601Holding current value
$1.32 Million% of portfolio
0.01%Shares
3 transactions
Others Institutions Holding ALLO
# of Institutions
162Shares Held
134MCall Options Held
59.4KPut Options Held
113K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$47.7 Million1.25% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$41.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.33MShares$21.2 Million0.0% of portfolio
-
State Street Corp Boston, MA7.01MShares$17.9 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$17.6 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $367M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...